Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare ConferenceGlobeNewsWire • 06/07/22
Wall Street Analysts Believe Lyell Immunopharma (LYEL) Could Rally 341%: Here's is How to TradeZacks Investment Research • 05/03/22
Lyell Immunopharma to Present Preclinical Data for Two Product Candidates in Clinical Development at ASGCT Annual MeetingGlobeNewsWire • 05/02/22
Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business HighlightsGlobeNewsWire • 03/29/22
Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 700% Upside Potential24/7 Wall Street • 03/12/22
Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2022 Annual MeetingGlobeNewsWire • 03/08/22
Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-Cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSKGlobeNewsWire • 01/24/22
Lyell Immunopharma Announces FDA Clearance of its IND for LYL797, a CAR T-Cell Therapy Incorporating Novel Reprogramming Technologies for Solid TumorsGlobeNewsWire • 12/16/21
Lyell Immunopharma Announces cGMP Qualification of LyFE™ Manufacturing Center in Advance of Initiating Clinical ProgramsGlobeNewsWire • 12/15/21
Lyell Immunopharma Reports Third Quarter 2021 Financial Results and Business HighlightsGlobeNewsWire • 11/12/21
Lyell Immunopharma Reports Second Quarter 2021 Financial Results and Business HighlightsGlobeNewsWire • 08/12/21